Crypto Briefing·
SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach
SELLAS' financial loss underscores the high stakes of its leukemia trials, potentially impacting future funding and strategic directions.
More news
- TokenPostXRP Ledger Proposal Would Restrict Withdrawals From New Broker Vaults During Investment
- TokenPostTokenized Cerebras Systems Share (CBRS) Gains 11.8% in One Hour
- Crypto BriefingAnthropic updates usage policy to curb abuse of its Claude chatbot
- TokenPostTwist Bioscience Targets Up to $560 Million in FY2027 Revenue
- CryptoSlateAnthropic’s new AI leads freelance benchmarks, yet fails 58% of the tasks
- TokenPostGrin (GRIN) Gains 10.85% in an Hour, Reaching $0.012759